Tradestie Institutional Equity Comparison Engine

NUVB vs JANX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NUVB Overall Edge

NUVB Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nuvation Bio Inc. (NUVB) driven by superior Growth & Margin, Momentum & Technical while JANX counters with relative strength in Options & Structure. Fundamentally, NUVB trades at N/M Forward P/E with -61.2% operating margin (+242.6% YoY revenue) versus JANX at N/M Forward P/E and -599.3% operating margin (-7.1% YoY). In options structure, NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against JANX sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
NUVB N/M vs JANX N/M Fwd P/E
Growth & Margin Winner NUVB
Op Margin -61.2% vs -599.3% ยท YoY +242.6% vs -7.1%
Momentum & Technical Winner NUVB
1Y -46.9% vs -65.0% ยท 52W Pos 2% vs 0%
Options & Structure Winner JANX
BREAKDOWN (26th %ile IV) vs BREAKDOWN (17th %ile IV)
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
1M Return -19.15%
1Y Return -46.85%
Forward P/E N/M
Unified AI Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
JANX NASDAQ
Janux Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$10.08
-2.04% 1D
Market Cap $629.6M
1M Return -40.91%
1Y Return -65.01%
Forward P/E N/M
Unified AI Score
50.8 / 100 HOLD
Tech 45.0 Fund 56.0 Flow 67.0 Mom 55.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NUVB -46.85% JANX -65.01% Spread: +18.16 pp (NUVB Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NUVB Revenue JANX Revenue NUVB Op. Margin JANX Op. Margin Margin Edge
FY2021 N/A $0M N/A -905.4% JANX
FY2022 N/A $10M N/A -779.0% JANX
FY2023 N/A $10M N/A -902.9% JANX
FY2024 $10M $10M -7527.3% -933.6% JANX
FY2025 $60M $10M -338.7% -1576.7% NUVB

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NUVB (6) vs JANX (2)
Institutional Metric NUVB JANX Criterion Row Winner
Market Capitalization Scale $1.3B $629.6M Larger Scale NUVB
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +242.6% -7.1% Higher Growth NUVB
Operating Margin (TTM) Profitability -61.2% -599.3% Higher Margin NUVB
Net Profit Margin Profitability -67.4% 0.0% Higher Margin JANX
Return on Equity (ROE) Capital Efficiency -49.1% -10.6% Higher ROE JANX
52-Week Range Position Momentum 2% ($4โ€“$10) 0% ($10โ€“$35) Stronger Trend NUVB
Beta / 30D Volatility Risk Regime 1.52ฮฒ ยท 55% Vol 0.69ฮฒ ยท 114% Vol Lower Realized Risk NUVB
Unified Institutional Score Composite Signal 61.0 / 100 (BUY) 50.8 / 100 (HOLD) Higher Composite NUVB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NUVB vs JANX Buy Guide
NUVB BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NUVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
JANX BREAKDOWN
55d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live JANX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NUVB nor JANX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.